参考文献/References:
[1]Perdonà S,Bruzzese D,Ferro M,et al.Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy[J].Prostate,2013,73(3):227-235.
[2]Matteo Ferro,Dario Bruzzese,Sisto Perdona,et al.Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml[J].PLoS One,2013,8(7):e67687.
[3]叶定伟,朱耀.中国前列腺癌的流行病学概述和启示[J].中华外科杂志,2015,53(4):249-252.
[4]Surveillance,Epidemiology,and End Results(SEER)Program.SEER Site recode[EB/OL].[2013-08-06].http://seer.cancer.Gov/sitereeode/iedo3-d01272003/.
[5]Matsuda T,Ajiki W,Marugame T,et al.Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan:a chronological and international comparative study[J].Jpn J Clin Oncol,2011,41(1):40-51.
[6]Jansen FH,van Schaik RH,Kurstjens J,et al.Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection[J].Eur Urol,2010,57(6):921-927.
[7]Sokoll LJ,Chan DW,Mikolajczyk SD,et al.Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range:preliminary analysis[J].Urology,2003,61(2):274-276.
[8]Foley RW,Gorman L,Sharifi N,et al.Improving multivariable prostate cancer risk assessment using the Prostate Health Index[J].BJU Int,2016,117(3):409-417.
[9]Catalona WJ,Partin AW,Sanda MG,et al.A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range[J].J Urol,2011,185(5):1650-1655.
[10]Chiu PKF,Roobol MJ,Teoh JY,et al.Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume[J].International Urology & Nephrology,2016,48(10):1631-1637.
[11]Ng CF,Chiu PK,Lam NY,et al.The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/ml[J].International Urology and Nephrology,2014,46(4):711-717.
[12]周保同,韦尔东,何天基,等.前列腺健康指数对前列腺癌诊断价值的Meta分析[J].安徽医科大学学报,2018,53(07):1089-1095.
[13]Stephan C,Kahrs AM,Cammann H,et al.A (-2)proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases[J].The Prostate,2009,69(2):198-207.
[14]Lazzeri M,Briganti A,Scattoni V,et al.Serum index test %[-2] proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy[J].J Urol,2012,188(4):1137-1143.
[15]Loeb S.Prostate Health Index (PHI): golden bullet or just another prostate cancer marker?[J].Eur Urol,2013,63(6):995-996.
[16]Tosoian JJ,Druskin SC,Andreas D,et al.Prostate health index density improves detection of clinically-significant prostate cancer[J].BJU Int,2017,120(6):793-798.
[17]Rhodes T,Jacobson DJ,McGree ME,et al.Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men[J].Urology,2012,79(3):655-661.
[18]Lazzeri M,Abrate A,Lughezzani G,et al.Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA),%p2PSA,and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination[J].Urology,2014,83(3):606-612.
[19]Lughezzani G,Lazzeri M,Larcher A,et al.Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy[J].J Urol,2012,188(4):1144-1150.
[20]Stephan C,Vincendeau S,Houlgatte A,et al.Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer[J].Clin Chem,2013,59(1):306-314.
[21]Fossati N,Buffi NM,Haese A,et al.Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives,%p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer:Results from a Multicentric European Prospective Study[J].Eur Urol,2015,68 (1):132-138.
[22]Loeb S,Shin SS,Broyles DL,et al.Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer[J].BJU Int,2017,120(1):61-68.
[23]Wang W,Wang M,Wang L,et al.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer:a meta-analysis[J].Sci Rep,2014(4):5012.
[24]Chiu PK,Lai FM,Teoh JY,et al.Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy[J].Ann Surg Oncol,2016,23(8):2707-2714.
[25]吴义启,刘修恒.前列腺特异性抗原前体2型及其百分比、前列腺健康指数对前列腺癌的诊断价值[J].现代泌尿外科杂志,2015,20(7):525-527.
相似文献/References:
[1]廖 祺,黄 一,徐 雪.前列腺癌骨转移的疼痛管理[J].医学信息,2018,31(06):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
LIAO Qi,HUANG Yi,XU Xue.Pain Management of Bone Metastasis in Prostate Cancer[J].Journal of Medical Information,2018,31(23):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
[2]袁长翮.超声引导下经直肠前列腺穿刺诊断前列腺癌的价值研究[J].医学信息,2018,31(04):156.[doi:10.3969/j.issn.1006-1959.2018.04.058]
YUAN Chang-he.The Value of Ultrasound Guided Transrectal Prostate Puncture in the Diagnosis of Prostate Cancer[J].Journal of Medical Information,2018,31(23):156.[doi:10.3969/j.issn.1006-1959.2018.04.058]
[3]胡春燕,吴天天,王 殊,等.前列腺癌患者自我感受负担及其影响因素研究[J].医学信息,2018,31(13):173.[doi:10.3969/j.issn.1006-1959.2018.13.054]
HU Chun-yan,WU Tian-tian,WANG Shu,et al.Study on Self-perceived Burden and its Influencing Factors in Patients with Prostate Cancer[J].Journal of Medical Information,2018,31(23):173.[doi:10.3969/j.issn.1006-1959.2018.13.054]
[4]张 莹,谢 静.前列腺癌预后标志的研究[J].医学信息,2019,32(09):7.[doi:10.3969/j.issn.1006-1959.2019.09.003]
ZHANG Ying,XIE Jing.Prognostic Markers of Prostate Cancer[J].Journal of Medical Information,2019,32(23):7.[doi:10.3969/j.issn.1006-1959.2019.09.003]
[5]袁也晴,张学齐,汪青蓉,等.KIF14在前列腺癌细胞中的表达及作用[J].医学信息,2019,32(09):68.[doi:10.3969/j.issn.1006-1959.2019.09.022]
YUAN Ye-qing,ZHANG Xue-qi,WANG Qing-rong,et al.Expression and Role of KIF14 in Prostate Cancer Cells[J].Journal of Medical Information,2019,32(23):68.[doi:10.3969/j.issn.1006-1959.2019.09.022]
[6]胡嘉莉,华 琳.miRNA-mRNA双重表达谱在前列腺癌分子调控机制中的作用[J].医学信息,2022,35(16):18.[doi:10.3969/j.issn.1006-1959.2022.16.004]
HU Jia-li,HUA Lin.Role of miRNA-mRNA Dual Expression Profile in Molecular Regulation of Prostate Cancer[J].Journal of Medical Information,2022,35(23):18.[doi:10.3969/j.issn.1006-1959.2022.16.004]
[7]王 乾,孙 宾,李殷南,等.尿液中肌氨酸、PCA3mRNA在前列腺癌
早期诊断中的应用[J].医学信息,2019,32(14):175.[doi:10.3969/j.issn.1006-1959.2019.14.059]
WANG Qian,SUN Bin,LI Yin-nan,et al.Application of Urinary Sarcosine and PCA3mRNA in Early Diagnosis of Prostate Cancer[J].Journal of Medical Information,2019,32(23):175.[doi:10.3969/j.issn.1006-1959.2019.14.059]
[8]李熹阳,谷明宇,华 琳.影响前列腺癌风险的关键基因识别[J].医学信息,2020,33(02):80.[doi:10.3969/j.issn.1006-1959.2020.02.022]
LI Xi-yang,GU Ming-yu,HUA Lin.Identification of Key Genes Affecting Prostate Cancer Risk[J].Journal of Medical Information,2020,33(23):80.[doi:10.3969/j.issn.1006-1959.2020.02.022]
[9]黄 鹏,廖鑫鑫,陆文宝,等.临床评分系统预测前列腺癌根治术后生化复发的研究[J].医学信息,2020,33(08):76.[doi:10.3969/j.issn.1006-1959.2020.08.025]
HUANG Peng,LIAO Xin-xin,LU Wen-bao,et al.Clinical Scoring System Predicts the Value of Biochemical Recurrence after Radical Prostatectomy[J].Journal of Medical Information,2020,33(23):76.[doi:10.3969/j.issn.1006-1959.2020.08.025]
[10]陈彦君,刘建萍,龚志勇.预测前列腺癌根治术后生化复发的研究[J].医学信息,2021,34(05):49.[doi:10.3969/j.issn.1006-1959.2021.05.015]
CHEN Yan-jun,LIU Jian-ping,GONG Zhi-yong.Study on the Prediction of Biochemical Recurrence After Radical Prostatectomy[J].Journal of Medical Information,2021,34(23):49.[doi:10.3969/j.issn.1006-1959.2021.05.015]